ANI Pharmaceuticals (NASDAQ:ANIP) held its virtual annual meeting of stockholders, with shareholders approving all proposals presented, including the election of directors, ratification of the company’s auditor and approval of an amended stock incentive plan.
President and Chief Executive Officer Nikhil Lalwani chaired the meeting. Meredith Cook, the company’s General Counsel and Corporate Secretary, served as secretary for the meeting, and Tony Caradello of the Caradello Group served as Inspector of Election.
Shareholders Elect Directors Through 2027
- Thomas J. Haughey
- Nikhil Lalwani
- Matthew J. Leonard
- Antonio R. Pera
- Muthuswamy Shanmugam
- Renee P. Tannenbaum
- Jeanne A. Thoma
Lalwani also recognized outgoing board chairman Patrick D. Walsh, noting that the company had previously announced in December 2025 that Walsh would retire and step down as chairman and as a director after seven years of service.
“I would like to take this opportunity to thank Pat for his mentorship, guidance, and support, and to wish him all the best in his retirement,” Lalwani said.
Lalwani also acknowledged Thomas J. Haughey’s contributions as a director over the past seven years and welcomed him as the company’s next chairman.
Auditor, Executive Pay and Stock Plan Approved
Shareholders ratified the appointment of Ernst & Young LLP as ANI Pharmaceuticals’ independent registered public accounting firm for the fiscal year ending Dec. 31, 2026. Joe Wagner of Ernst & Young was present and available to answer appropriate questions during the meeting’s question-and-answer period.
Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers. In a separate advisory vote, shareholders indicated a preference for future advisory votes on executive compensation to be conducted every year.
The company’s Amended and Restated 2022 Stock Incentive Plan was also approved.
Quorum and Voting Details
According to the meeting report, as of the close of business on March 23, 2026, ANI had 22,750,198 shares of common stock and 10,864 shares of Class C special stock outstanding and entitled to vote, with each share entitled to one vote. The company said a quorum was present based on the tabulation of proxies received from shareholders.
Cook said the meeting notice, proxy statement, proxy card and annual report for the fiscal year ended Dec. 31, 2025, were made available electronically or by mail on or about April 9, 2026, to stockholders of record as of March 23, 2026.
Lalwani said the company will file a Form 8-K reporting final voting results within four business days of the meeting’s conclusion.
No Shareholder Questions Submitted
After the formal business was completed and the meeting was adjourned, ANI opened a question-and-answer period. Company representatives said no questions had been submitted.
“I want to thank you again for attending today’s meeting and for the interest that you have shown in the company,” Lalwani said. “We very much appreciate your attendance, and as always, thank you for your support.”
About ANI Pharmaceuticals (NASDAQ:ANIP)
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
